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Physical sciences/Nanoscience and technology/Other nanotechnology/Environmental, health and 
safety issues [URI 639/925/929/170] 
 
Long-term surveillance for nanomedicine implants and drugs 
Michaela Kendall and Iseult Lynch 
 
Increasing globalization means that traditional occupational epidemiological approaches may no 
longer apply, suggesting a need for an alternative model to assess the long term impact of 
nanomaterial exposure on health.  
 
The Royal Society conference “Bionano Interactions: new tools, insights and impacts” (30 April – 1 
May 2014) discussed translating potential nanobiotechnologies into clinical applications, and 
assessed their safety and science-based regulatory regimes1.  A key topic of debate was whether 
nanomaterials and nanostructures require additional or alternative risk assessment approaches, and 
what form these might take.  In exposure assessment, it was suggested that occupational 
epidemiology approaches may no longer apply because of increased globalization, where material 
production has become geographically dispersed and consumer purchasing patterns have changed. 
Instead, exposure to nanomedicines (e.g. diagnostics such as contrast agents or therapeutics such as 
drug delivery agents) and nano-structured implants may represent a significant new exposure route 
or cohort for epidemiological studies of nano-related health effects2.   
 
Traditionally, occupation-centric epidemiology – where worker populations are studied over decades 
- is used to assess the impact of material exposure on health. Accumulated evidence from such 
studies in specific industries (such as mining, agriculture, radiation workers and others) have alerted 
observers to common, damaging occupational material exposures, mechanisms and effects.  In cases 
of extreme exposure to a work-related contaminant, it was possible to quantify the level of exposure 
and the effects on health. Worker cohorts were key to identifying the damaging health effects from 
inhalation of the crocidolite form of asbestos, which is linked to pleural mesothelioma, a form of 
lung cancer2. Building on these studies, environmental exposures in non-occupational settings 
became possible. For example, lung and cardiovascular related health impacts from anthropogenic 
airborne particles have been correlated with exposure via measures such as closeness to busy roads 
or traffic3, and assessment of health effects from exposure to airborne nanomaterials has also been 
tested. 
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In the case of nanomaterials, safety assessment is approached from a responsible governance of 
innovation viewpoint, to prevent large-scale human health impact, such as that from asbestos4.  The 
field of nanotoxicology emerged from the study of fine (0.1-2.5 microns in diameter) and ultrafine 
(diameters <100nm) combustion or air-pollution particles (also called incidental particles) in the 
early-2000s, and it focuses specifically on health impacts from engineered or manufactured 
nanomaterials.5  Donaldson et al. recently rejected the idea that engineered nanomaterials may 
induce specific health effects beyond those already known for combustion-derived particles, such as 
inflammation and oxidative stress6.  However, novel features of some engineered nanomaterials, 
such as an energy bandgap that overlaps with that of cells, or very high surface strain resulting from 
high temperature synthesis methods, may result in enhanced toxicities compared to ultrafine 
particles from combustion or air pollution1.  Because health impacts linked to incidental or 
occupational exposures to engineered nanomaterials are minimal at current usage levels, few nano-
specific health effects have been determined by epidemiology, to date7.  However, from a regulatory 
viewpoint, in addition to acute effects, cumulative exposures that result in increased incidence of 
diseases are also important considerations. Indeed, many diseases are increasingly linked to 
environmental factors8 but only manifest after several decades (e.g. dementia, or asbestos-related 
mesothelioma).       
 
Although practices vary considerably between countries and in industries of different scales (e.g. 
small and medium enterprises versus corporations), decades of advances in legal protection and 
increased worker awareness have effectively reduced occupational exposures to materials such as 
airborne particles to low risk levels. Most of the protective practices developed for powder handling 
are applicable to nanomaterials, and if adhered to, will protect workers against occupational nano-
health effects9,10.   
 
At the recent Safety of Engineering Nanomaterials and Nanotechnologies (SENN2015) conference, 
Paul Schulte from the US National Institute for Occupational Safety and Health stated that worker 
populations in individual companies handling nanomaterials are too small to monitor, and that even 
fewer workers are registered in medical surveillance or epidemiological studies (see Figure 1a). 
Furthermore, changes in production methods and the globalisation of businesses mean that the 
nature of exposures is also changing. Because the manufacturing, release and distribution of 
products to global markets now operate on more compressed timelines than before, long term 
exposures amongst workers are diminishing. Moreover, as material supply, handling and 
manufacturing facilities become more geographically dispersed (over various different continents), 
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the intensity of exposure is reduced.  All these point to the fact that workers may no longer 
represent the highest exposure group for epidemiological studies, including those related to 
nanomaterials.  Schulte concluded that even after 15 years of dedicated nano-industry activities, it 
has not yet been possible to make decisions regarding the risks faced by workers handling 
nanomaterials.  
 
Globalisation also makes data gathering much more complex.  Exposure to nanomaterials is 
particularly interesting because evidence of health consequences of occupational exposures is 
emerging slower than the commercialisation of mass-marketed nano-containing consumer products. 
Occupational safety and health criteria defining what constitutes responsible development of 
nanotechnology are missing11.   The economic positives of nanomaterial deployment have trumped 
almost all human health concerns over new materials entering products, markets, humans and the 
environment12.  Nanomaterials are now included in a wide range of consumer products (>1,600 
according to the Woodrow Wilson consumer product inventory13), and have been particularly taken 
up by cosmetics manufacturers14,15.  This has led to a flurry of regulatory-related activity in Europe, 
the US, and elsewhere. For example, in 2014, the US Food and Drug Administration issued guidance 
for the cosmetics industry16 that requires manufacturers or distributors to identify and appropriately 
address new or altered physicochemical properties exhibited by nanomaterials that affect biological 
interactions, or raise questions about product safety. Specifically, this requires assessing the 
suitability of traditional methods for testing the toxicity of cosmetic products containing 
nanomaterials.16   In Europe (effective since July 2013, with other jurisdictions likely to follow suit in 
the near future), it is required to include (nano) in front of nanoscale ingredients on cosmetics labels 
and packaging.    
 
Another area of very rapid growth, with significantly higher market value and much tighter 
regulation, is the use of nanomaterials in medicine. This extends from nanostructured scaffolds and 
biomaterials for growth and repair of tissue in regenerative medicine, through use of nanoscale 
carriers for improving drug solubility and enhancing target specificity of drug molecules, to imaging 
and diagnostic applications of nanomaterials as contrast agents or as combined diagnostic and 
theranostic agents.17  We propose here that the intentional use of nanomedical products provides a 
new route to monitor the health impacts from exposure to nanomaterials, both intentional (the 
patient) and potentially occupational (clinical staff), and provide some specific examples below.   
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The biomaterials market for implantable devices was valued at US$25.3 billion in 2012 and is 
estimated to reach US$33.6 billion globally in 2019, driven by the rising need for medical implants in 
key growth markets including the U.S., U.K., Canada, Germany, France, Japan, Australia, South Korea 
and New Zealand.18   Among the factors that are driving the increased implantation of materials into 
the human body is the aging global population which is pushing up demand for e.g. hip and knee 
replacements. Longer lifespans mean that implant recipients can coexist with their implant for 
increasingly long durations; although designed to last 15-20 years, some implants last as long as 30-
40 years.  The rapid rise in implant procedures globally has occurred without understanding 
potential long-term effects of the materials, and there remains strong concern about wear (both 
abrasion and leakage) and autoimmunity19.  Evidence is mounting that, over time, nanoscale “wear 
particles”, which are formed as a result of wear to load-bearing implants such as hip-joints, can 
migrate from the implant site, signal across the blood-foetal barrier and cause damage to DNA 20,21.  
This, along with evidence of short-term complications and high failure rates leading to additional 
surgeries, led to the UK National Health Service banning the use of metal-on-metal hip implants in 
October 2013, with the United States and Canada later recommending they not be used22.   Events at 
the implant surface can also affect implant function.  Analysis of the so-called foreign body reaction 
(FBR), one of the major routes of failure of medical implants, demonstrated that disease 
mechanisms were often related protein adhesion and subsequent interaction of phagocytes with the 
surface-adsorbed proteins19.  The use of nanostructured surfaces offers a strategy to enhance 
acceptance of implant materials (see Figure 2) through mediation of protein binding.  Other nano-
enabled approaches under development include  
cell encapsulation in injectable multifunctional hydrogels for cell delivery and nanostructured 
scaffolds for complex tissues generation.17 
 
The nanomedicine and nanodiagnostics markets are also expanding, driven by the demand for 
earlier diagnosis (via increased sensitivity and/or improved spatial resolution of contrast agents) 
and/or improved efficacy and specificity of therapies for widespread diseases such as cancer.  
Recent market reports have valued the nanomedicine market at US$72.8 billion in 2011 and it is 
expected to grow to $130.9 billion by 201623.  The pharma patent gap – arising from the lack of new 
patented drugs and expiry of patented drugs - has pushed the commercialization of nano-enabled 
innovations.  Nanoformulation creates new hope for drug candidates that failed to reach the market 
previously, because nanomaterials, which are at the same size scale as molecular biology, offer 
enormous potential to improve the delivery and efficacy of existing drug formulations.  For example, 
poorly soluble or highly toxic drugs can be encapsulated into nanocarriers (in the form of liposomes 
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or polymeric nanoparticles) to improve their specificity and safety profiles.24  Drugs with poor target 
specificity can be delivered directly to the target cells, thus reducing the dose required and the side-
effects.24  Numerous FDA-approved nanotherapeutics and nanodiagnostics are available for clinical 
use (see Table 1 for a subset as examples), as well as many more in clinical trials25.  However, several 
nano-diagnostic products that have undergone extensive clinical trials were later withdrawn from 
the market or denied marketing authorisation (e.g. superparamagnetic iron oxide formulations 
Resovist® and SINEREM®) as a result of poor specificity and/or poor contrast leading to a high 
proportion of false negatives.  
 
Given the uncertainty regarding the safety of nanomaterials, longer term surveillance of patients 
(e.g. weeks, months and years following exposure) during early and advanced clinical trial phases is 
needed. Close monitoring of patients is important for identifying any long-term consequences, which 
could be used in product development.  Better products are likely to reduce the number of recalls. 
An important area of development is delivery systems for the respiratory tract, including nasal, 
tracheobronchial and pulmonary regions, for less invasive treatment of chronic illnesses such as 
diabetes (see also Figure 2)26 27.  While these are not yet in clinical use, tracking both patient and 
medical worker exposures to inhalable nanomedicines as they come onto the market could provide 
important links to occupational exposure monitoring, where inhalation is the primary exposure 
route. 
 
The use of nanomaterials and other advanced materials in contemporary clinical practice could be a 
particular concern because of the unpredictable effects of cumulative nanoparticle exposures from 
many sources, including those from medical procedures and general consumer exposure to 
nanomaterials-containing products.  Thus, humans are likely to experience high exposures – and 
potentially doses – of certain nanomaterials from implantation and/or use of nano-enhanced 
medicinal products.  Clinically prescribed doses of nanomedicines or nanodiagnostic agents are likely 
to be higher than occupational exposures.  Additionally, medical exposures will occur against a 
background of anthropogenic atmospheric exposures (e.g. from combustion) and from other sources 
such as food (typical exposure for a US adult may be ~1 mg Ti per kilogram body weight per day).28  
Indeed, a more comprehensive approach that assesses the "exposome", i.e. “the totality of 
exposures throughout a person's life, from chemicals, diet, stress, drugs, infection, and the individual 
response”, has been called for29.  The highly specific composition of medical implants (e.g. the CoCr 
debris particles from metal-on-metal hip implants20) is advantageous in terms of identification and 
tracking nanomaterials in patients.  Similarly, nanodiagnostic tools such as gold or iron oxide 
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particles used as contrast agents should be easily detectable, and their long-term fate could be 
tracked following administration.  For difficult to detect nanomedical carriers such as polymeric 
particles, or where no significant accumulation occurs in the body, approaches to monitoring 
exposure using treatment dose are feasible.  Such approaches are currently used to track patient 
exposure to X-rays for example, as well as monitoring immunisation throughout childhood via 
national immunisation programmes.  Using increasingly sophisticated patient tracking systems like 
patient accessible electronic health records (PAEHRs),30 public health professionals may monitor the 
exposure of patients to nanomedicine, and analyse the health implications of nanomedicines or 
implants over years or decades 31. With proper due diligence and collaboration, the fields of 
nanomedicine and public health have the potential to accelerate each other to improve human 
health more efficiently than either could do individually31.   
 
The toxicological study of nanomedicines and implants is critically important, yet it remains difficult 
to detect chronic effects since there are few long-term studies in toxicology, and only (occupational) 
epidemiology tends to demonstrate chronic effects.  However, evidence for the success or otherwise 
of implants is emerging from medical practice via clinical trials data, and as a result of product re-
calls or bans.  Patients treated with nanomedicines and nanodiagnostics continue to face a 
knowledge gap regarding epidemiology studies, unless some specific action is taken to monitor the 
use of nano-enabled theranostic approaches, and to implement medical surveillance following nano-
related treatment.  Clearly, such approaches cannot account for self-mediation, whereby the 
internet has reduced geographical boundaries in terms of availability of products, including 
medicines and dietary supplements, even where regulation regarding specific products and their 
safety exists. Thus, patient self-reporting of exposure might supplement surveillance. Importantly, 
the potential of nanomedicine is not limited to developed countries: public health applications of 
nanomedicine, such as rapid and portable diagnostics and more effective vaccinations, have the 
potential to revolutionize global health.31  Thus, global best practice for monitoring the use and long-
term post-treatment consequences of nanomedicines needs to be established urgently.  
 
As our previous reliance on worker exposure data is undermined by globalisation, advances in 
industrial production and changes in consumer purchasing patterns, nano-exposure related effects 
are challenging to detect and define.  Along with voluntary or mandatory registries of products 
containing nanomaterials, mandatory hospital and clinical registries that record the use of nano-
enabled or nano-containing medicines and devices for longitudinal epidemiological studies may be 
necessary in order to facilitate the necessary epidemiological studies. Such registries can identify 
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issues early on and mobilise a rapid response should product failures or adverse patient responses 
arise later on.  As utilisation of nanomedicines increase, such medical surveillance registries will 
demonstrate the importance of data collection in assessing both treatment success as well as 
potential unintended health consequences resulting from nanomedicine exposure.  There is 
precedent for medical surveillance following cancer diagnosis and/or treatment,32 and health-care 
related infections,33 which could be extended to nano-based diagnostic or treatment interventions 
(see Figure 1b).  Indeed, advances in classification and multivariable algorithms to analyse patient 
records and outcomes is improving the predictive capacity of the algorithms in terms of determining 
whether follow-up care is required and thus, improving the cost effectiveness of post-operative 
patient care33.  The role of public health professionals in achieving this is vital, and indeed there has 
already been a suggestion to form a science, technology, medicine law-healthcare policy (STML) 
center, to support the translation of nanotechnology across medical disciplines31.  This could provide 
a legal underpinning to support long-term (decades) surveillance and global sharing of data 
regarding long-term patient outcomes following treatment with nanomedicines.  Longitudinal 
studies of patients following implant treatment are common (e.g. over 25 years) and should be 
implemented more broadly for nanomedicines.  Coordinated approaches of this nature would also 
facilitate timely and coordinated responsive action should the need arise.  
 
Given the enormous scope of nanotechnologies, the reinsurance industry was among the first to 
publish reports on the potential risks of nanomaterials34,35.  In addition to employer liability and 
product liability losses, there could potentially be losses and/or lawsuits arising out of environmental 
liability,36 e.g. costs of repairing environmental damage arising from both common law claims, and 
claims arising from national, EU and international legislation. For example, the principle of the 
polluter pays is enshrined in the Treaty on the Functioning of the European Union (Article 191(2) 
TFEU) and in the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) 
of 1980 in the USA. One potential route towards a nanomedical surveillance programme is the use 
of health insurance records. However, this would not be without legal challenges and data privacy 
issues. An alternative model could be oversight partnerships between regulators, nanomedicine 
companies and hospital trusts to extend clinical trials into longer-term surveillance of patient 
outcomes for a number of years post regulatory approval, such that early warnings of undesirable 
impacts can be addressed rapidly and effectively.  This could be coupled with monitoring of patient 
responses to more traditional implant materials, such as metal-on-metal implants, which are 
increasingly understood to generate nanoparticles during extended use as a consequence of wear-
and-tear, to additionally monitor responses to unintentional exposure to nanomaterials. 
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Additionally, the doctors and nurses routinely handling nanomedicines could provide a parallel 
occupational exposure cohort.  Combined, these three groups (nanomedicine patients, 
nanomedicine hospital workers and traditional implant patients whose implants generated “wear-
induced nanoparticles”) would ensure large cohort sizes for epidemiological studies of impacts of 
exposure to nanoscale materials.  
 
Michaela Kendall1 and Iseult Lynch2 are at 1School of Metallurgy and Materials, University of 
Birmingham, Edgbaston, B15 2TT and 2School of Geography, Earth and Environmental Sciences, 
University of Birmingham, Edgbaston, B15 2TT, United Kingdom  
email: i.lynch@bham.ac.uk   
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Table 1: Examples of applications of nanomaterials in medicine, including diagnostics and implants and the relative market value of different areas 
Medical area Nanomaterials used Example products1 Market Value2 
Nanomedicines  
- Anticancer 
- Central nervous system 
- Anti-infective 
- Anti-inflammatory 
- Occular ageing 
- Cardiovascular 
 
Paclitaxel-loaded polymer micelle 
Polymer–drug conjugates 
Liposomal amphotericin B 
Polymer–protein conjugate  
PEG-anti-VEGF aptamer 
SPIONs (clinical trials) 
 
Genexol-PM® (Samyang Co., 2007) 
Copaxone® (Teva, 1996) 
Abelcet® (Sigma Tau, 1995) 
PEGINTRON®  (Schering Plough, 2000) 
Macugen® (Eyetech, 2004) 
 
 
28 US$Billion 
14 US$Billion 
9.3 US$Billion 
7.3 US$Billion 
- 
4 US$Billion 
Nanodiagnostics 
- MRI contrast agent 
- Circulating tumour cell detection 
- Lab-on-a-chip 
- Diagnostics - biomarkers 
 
Silicone-coated ferumoxsil SPIONs 
Antibodies bound to Iron Oxide NPs 
DNA-based tests 
Functionalized gold NPs 
 
Gastromark (AMAG Pharmaceuticals, 1996) 
CellSearch (Veridex, 2004) 
DNAarray (CombiMatrix, 2005) 
Verigene (Nanosphere, 2007) 
7.9 US$Billion3 
- 
- 
- 
- 
Implants and prosthetics 
- orthopaedic 
- wound management 
- dental / dental care products 
- cardiac implants 
- bone-replacement scaffold 
 
Nano hydroxyapatite 
Silver NP solution 
Nano hydroxyapatite 
Nanoporous hydroxyapatite  
Ultraporous beta-Tri-calcium phosphate NPs 
 
BoneSource (Lebinger) 
Silvagard (AcryMed Inc., 2005) 
UltraDEX® Recalcifying (Periproducts Ltd) 
Vestasync (MIV Therapeutics, Inc.) 
Vitoss (Orthovita, 2000) 
10.2 US$Billion3 
- 
- 
- 
- 
- 
1 Selected from references 37 and 25 or identified via web searches.  Detailed lists available in these reviews.   
2 2011 values for Global nanomedicine marked (US$Billions), from 38. All predicted to double by 2016.  – breakdown by class not available. 
3 Breakdown into sub-categories not available. 
Abbreviations in Table: DNA - deoxyribonucleic acid; NP – nanoparticle; PEG - Poly(ethylene glycol); SPIONs – super-paramagnetic iron oxide nanoparticles; VEGF - Vascular 
endothelial growth factor. 
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Figure 1: Illustration of the challenge in identifying suitable nanomaterial-exposed cohorts using 
the traditional occupational exposure paradigm.  (a) Functional categories of workers involved with 
nanomaterials are illustrated for a typical company (figure courtesy P. Schultz, NIOSH, presented at 
SENN 2015). Since only those workers that are exposed to nanomaterials, and enrolled in exposure 
registries including participating in an epidemiological research study (i.e. the sub-set of total 
workers indicated in yellow) are suitable for determination of exposure-related health impacts. The 
tiny proportion of employees in this category means that it is difficult to perform any meaningful 
occupational exposure-based risk assessment. (b) As a result of the challenges described in (a), 
alternative approaches for surveillance and epidemiological assessment of the potential health 
impacts resulting from exposure to nanomaterials are needed. The potential for a public health 
approach, via long-term post-treatment monitoring of patients treated with nanomedicines 
(therapies, diagnostics or implants), is proposed as one new model. This could be coupled with 
occupational monitoring of doctors and surgical teams involved in administration of nanomedicines.    
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Figure 2: Illustration of the range of application areas of nanomedicines.  Nano-implants, 
nanomedicines and nanodiagnostics are composed of a variety of materials. They can be metals, 
polymers, ceramics and naturally occurring biopolymer-derived materials that are either nanoporous 
or contain nanostructured surfaces, or formulated as nanoparticles for use as drug carriers or as 
contrast agents.  These nanomedicines are used to treat a range of diseases including cancer, 
cardiovascular, ocular ageing, and inflammatory and infective diseases (shown in blue italics in the 
figure). Nano-structured implants are used in several healthcare applications including cardiology, 
orthopaedics, dental, ophthalmology, aesthetic surgery, urology, neurology and gastroenterology 
(black text).  The structural and chemical bionano-interface of nanomedicines and nanodiagnostic 
tools determine their biodistribution to the target site, and is especially important for implants 
because the interfacial area is the site of greatest stresses in terms of mechanical wear, immune 
response and potential for infection.  
 
 
 
 
 
